Cingulate Therapeutics uses a unique combination of delivery technology and proven medications that creates an unmatched release profile.
Cingulate Therapeutics has raised $12.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2026.
Cingulate Therapeutics's investors include Werth Ventures, Lincoln Park Capital Fund, Falcon Creek Capital Advisor, Jeff Hargroves.
Cingulate Therapeutics is headquartered in Morristown, United States.
Cingulate Therapeutics uses a unique combination of delivery technology and proven medications that creates an unmatched release profile.
Cingulate Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cingulate Therapeutics — Funding & Investors." VCBacked, February 17, 2026, https://www.vcbacked.co/company/cingulate-therapeutics. Accessed November 14, 2026.
VCBacked. (2026). Cingulate Therapeutics — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/cingulate-therapeutics
{{cite web |title=Cingulate Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cingulate-therapeutics |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Cingulate Therapeutics? Request a listing update